Search Results
CAR-T Immunotherapy Showing Positive Results
This week, positive data from a Kite Pharma CAR-T immunotherapy clinical trial was released showing that more than one-third of refractory aggressive non-Hodgkin lymphoma (NHL) patients in the study showed no signs of the disease after six months.
Since 2015, The Leukemia & Lymphoma Society has been funding this study through its collaboration with Kite Pharma, a biotechnology company focused on immunotherapy.
Decitabine
Decitabine is FDA approved to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia.
Rasburicase
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
Nelarabine
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Tagraxofusp-erzs
Tagraxofusp-erzs is FDA approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older.
Ask the Doctor Part 1: Five Questions about Leukemia
Leukemia Survivor, Myrrah Talks to Dr. Nichols about the Latest in Leukemia Research and Treatment
Denileukin diftitox-cxdl
Denileukin diftitox-cxdl is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
From Fighting Fires to Fighting for His Life: One Firefighter’s Journey with Cancer
In late 2014, Eric Wirtz, a firefighter for the Boston Fire Department, lost his 64-year-old mother to pancreatic cancer. During that time he had been experiencing pain in his lower right back and hip area and frequent bouts of flu-like symptoms. Eric says that overall he “just did not feel too good.” Little did he know he was about to face his own battle with cancer. Tests of Eric’s lower abdominal area revealed a large tumor that were inflamed lymph nodes in his hip area.
LLS, advocates celebrate major state policy wins for patients
While Congress meets year-round, state legislatures typically meet only in the first half of the year. The start of the summer generally marks the end of the state sessions.
As LLS prepares for our 2024 state work, it’s important to celebrate the incredible wins we achieved at the state level in 2023.
These policies are the culmination of years of work from volunteers and LLS staff from across the organization. We hope you’ll take a moment to learn about them – and share them with your own stakeholders.
Ask the Doctor Part 3: Five Questions about Myeloma
Myeloma Survivor, Sharon Clark Talks to Dr. Nichols about the Latest in Myeloma Research and Treatment
HIGH SCHOOL STUDENTS 'TEST' THE LIMITS OF PHILANTHROPY
For the second year in a row, high school students across the country are redefining what it means to be philanthropic in today’s youth culture. Through The Leukemia & Lymphoma Society’s (LLS) newest innovation in fundraising, Students of the Year, more than 600 motivated high school students raised significant funds for LLS’s cutting-edge cancer research and patient services.
Midostaurin
Rydapt is FDA approved for the treatment of adult patients with:
- Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Limitations of Use:
RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. - Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
Enasidenib
Enasidenib (Idhifa®) is FDA approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.
One Family’s Inspiring Quest to Help Other Families Impacted By Cancer
A nasty cough and extreme fatigue first led Myrna and Lou Binder to bring their 12-year-old son, Jeff, to the doctor for an examination. But the flu-like symptoms persisted until more tests enabled the doctors to arrive at the shocking diagnosis: non-Hodgkin lymphoma. The year was 1975.
Highlights from ASH 2021
The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them.
Predisposing factors to leukemia
Table of contents:
LLS advocates helped North Carolina expand Medicaid
North Carolina Gov. Roy Cooper just signed Medicaid expansion into law, following years of advocacy from LLS volunteers and staff.
Once it takes effect, the bipartisan deal will make 600,000+ North Carolinians newly eligible for lifesaving care, including cancer screenings and treatment.
Lymphoma diagnosis, survival rate by age, prognosis, and treatment
Table of contents:
#ASH18: Update on Immunotherapy
Immunotherapy – harnessing the body’s immune system to fight disease – is rapidly becoming a mainstay of cancer treatment. The increasing interest in this field was clear at yesterday’s standing-room only symposium hosted by The Leukemia & Lymphoma Society in advance of the 60th ASH (American Society of Hematology) Meeting which officially kicks off today here in San Diego. Over the next few days more than 30,000 researchers and others connected to the blood cancers and other blood malignancies will gather to hear the latest data from clinical trials.
Why Monthly Giving Matters
Giving regularly over time = giving patients and survivors the chance for more time.
Monthly giving really deserves more credit—credit as a predictable, impactful funding force for our lifesaving and life-changing work. For The Leukemia & Lymphoma Society (LLS), the reliability of a regular gift helps to sustain cutting-edge research and to provide the free resources and support blood cancer patients and survivors need to live longer, better lives.
It’s about ongoing generosity. It’s about creating a lasting impact.
And...
A Hodgkin Lymphoma Survivor’s “New Normal”
My life with cancer began five days before my wedding when I was 25 years old. On August 2, 2004, I was at a family birthday party when I felt a lump protruding out of my neck. After the party, I rushed over to see my stepdad who is a doctor.
Although he knew that the position of the lump at my age was not a good sign, he calmed me down and gave me antibiotics. After months of planning for the wedding, he knew how important it was for me to walk down the aisle.